Free Trial

Halozyme Therapeutics (HALO) Competitors

Halozyme Therapeutics logo
$77.57 -0.71 (-0.91%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$77.75 +0.18 (+0.23%)
As of 09:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HALO vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, IONS, MDGL, and RGEN

Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

Halozyme Therapeutics vs. Its Competitors

Halozyme Therapeutics (NASDAQ:HALO) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 2.9% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Biogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Halozyme Therapeutics currently has a consensus target price of $69.89, indicating a potential downside of 9.90%. Biogen has a consensus target price of $181.65, indicating a potential upside of 30.40%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Halozyme Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Halozyme Therapeutics
2 Sell rating(s)
4 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.42
Biogen
0 Sell rating(s)
21 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.32

Halozyme Therapeutics has a net margin of 47.28% compared to Biogen's net margin of 15.31%. Halozyme Therapeutics' return on equity of 150.85% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Halozyme Therapeutics47.28% 150.85% 29.19%
Biogen 15.31%13.85%8.32%

In the previous week, Biogen had 4 more articles in the media than Halozyme Therapeutics. MarketBeat recorded 28 mentions for Biogen and 24 mentions for Halozyme Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.08 beat Biogen's score of 1.04 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Halozyme Therapeutics
12 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
10 Very Positive mention(s)
6 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive

Halozyme Therapeutics has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Biogen has higher revenue and earnings than Halozyme Therapeutics. Biogen is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Halozyme Therapeutics$1.02B8.94$444.09M$4.3717.75
Biogen$9.68B2.11$1.63B$10.4613.32

Summary

Halozyme Therapeutics beats Biogen on 11 of the 17 factors compared between the two stocks.

Get Halozyme Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HALO vs. The Competition

MetricHalozyme TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$9.16B$3.16B$5.76B$10.50B
Dividend YieldN/A2.36%5.53%4.58%
P/E Ratio17.7521.0476.1826.62
Price / Sales8.94252.06471.1091.77
Price / Cash16.8346.3537.4661.85
Price / Book27.129.7813.776.45
Net Income$444.09M-$52.73M$3.29B$271.57M
7 Day Performance2.32%3.16%1.84%2.61%
1 Month Performance8.01%4.69%4.05%7.28%
1 Year Performance38.02%16.37%79.30%29.60%

Halozyme Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HALO
Halozyme Therapeutics
4.5559 of 5 stars
$77.57
-0.9%
$69.89
-9.9%
+32.5%$9.16B$1.02B17.75390Positive News
Analyst Forecast
Insider Trade
BIIB
Biogen
4.7309 of 5 stars
$143.32
-1.1%
$181.65
+26.7%
-28.9%$21.24B$9.68B13.707,605Trending News
UTHR
United Therapeutics
4.5242 of 5 stars
$403.11
-0.5%
$438.85
+8.9%
+22.1%$18.27B$2.88B15.731,305Insider Trade
INCY
Incyte
4.7613 of 5 stars
$83.14
+0.0%
$82.53
-0.7%
+31.8%$16.23B$4.24B18.902,617Positive News
Analyst Forecast
NBIX
Neurocrine Biosciences
4.4555 of 5 stars
$140.44
-1.0%
$160.00
+13.9%
+24.3%$14.07B$2.36B41.551,800Positive News
Analyst Forecast
EXEL
Exelixis
4.6648 of 5 stars
$39.01
-0.4%
$44.06
+12.9%
+51.0%$10.54B$2.17B18.751,147Positive News
BMRN
BioMarin Pharmaceutical
4.9638 of 5 stars
$53.14
-1.8%
$92.04
+73.2%
-22.7%$10.39B$2.85B15.773,040Positive News
EXAS
Exact Sciences
4.7818 of 5 stars
$53.43
-0.9%
$68.05
+27.4%
-24.7%$10.21B$2.76B-9.847,000
IONS
Ionis Pharmaceuticals
4.0904 of 5 stars
$61.10
-3.3%
$67.88
+11.1%
+49.6%$10.07B$705M-33.211,069Trending News
Analyst Forecast
MDGL
Madrigal Pharmaceuticals
3.901 of 5 stars
$425.60
-1.5%
$483.38
+13.6%
+96.4%$9.60B$180.13M-33.1290
RGEN
Repligen
4.8801 of 5 stars
$113.74
+0.2%
$166.67
+46.5%
-11.7%$6.39B$634.44M-454.941,778Analyst Upgrade

Related Companies and Tools


This page (NASDAQ:HALO) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners